Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
GBG Forschungs GmbH
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Stemline Therapeutics, Inc.
Wake Forest University Health Sciences
University of California, San Francisco
Washington University School of Medicine
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Virginia Commonwealth University
Alliance for Clinical Trials in Oncology
Ohio State University
Eastern Cooperative Oncology Group
AstraZeneca
M.D. Anderson Cancer Center
Bayer
Varian, a Siemens Healthineers Company
Fred Hutchinson Cancer Center
Spotlight Medical
AstraZeneca
Cedars-Sinai Medical Center
The Methodist Hospital Research Institute
Seagen Inc.
Eli Lilly and Company
Sichuan Baili Pharmaceutical Co., Ltd.
Corewell Health East
King's College London
Dana-Farber Cancer Institute
Weill Medical College of Cornell University
University of California, San Francisco
City of Hope Medical Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
MOMA Therapeutics
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Hoffmann-La Roche
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BicycleTx Limited
Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)